There is now convincing evidence that early cancer detection can lead to better patient outcomes through early administration of therapy. One of the best ways to early diagnose cancer is to use serum biomarkers. Unfortunately, for most cancers, we do not have effective biomarkers for either early detection or prediction of therapeutic response. With this grant application, we aim to identify such biomarkers for ovarian cancer - the most lethal gynecological malignancy in the United States. The major objective of this grant application is to examine if a panel of newly discovered ovarian cancer biomarkers (via an integrated systems biology proteomic approach), in combination with the classical ovarian cancer biomarker, CA125 and 9 other promising biomarkers such as HE4 and a group of kallikrein enzymes, constitutes a new, multiparametric serum panel for early ovarian cancer diagnosis with high sensitivity and specificity. By employing immunoassays and immuno-mass spectrometry-based technologies, we will perform a Phase I preclinical study on our top 40 novel biomarkers from which we will select only those displaying 98% specificity and 30% sensitivity for Phase II evaluation. The Phase ll case-control study, using validated immunoassays developed as part of this grant application, will utilize the PRoBE study design for sample collection and only those markers displaying at least 98% specificity and at least 70% sensitivity will proceed for an independent, blinded study using the EDRN CVC ovarian cancer reference sample set. It is anticipated that 2-4 new candidates, along with some of the 10 known markers will constitute a multiparametric panel with high specificity and sensitivity, suitable for early diagnosis and possible screening for ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA152755-05
Application #
8875577
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (M1))
Program Officer
Patriotis, Christos F
Project Start
2010-09-01
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
5
Fiscal Year
2014
Total Cost
$257,249
Indirect Cost
$18,392
Name
MT Sinai Hosp-Samuel Lunenfeld Research Institute
Department
Type
DUNS #
208808949
City
Toronto
State
ON
Country
Canada
Zip Code
M5 3-L9
Leung, F; Dimitromanolakis, A; Kobayashi, H et al. (2013) Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. Clin Biochem 46:1462-8
Kosanam, Hari; Prassas, Ioannis; Chrystoja, Caitlin C et al. (2013) Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Mol Cell Proteomics 12:2820-32